Morgan Stanley’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.24K | Buy |
1,964
+668
| +52% | +$1.78K | ﹤0.01% | 7021 |
|
|
2025
Q1 | $10.4K | Buy |
1,296
+299
| +30% | +$2.4K | ﹤0.01% | 6786 |
|
|
2024
Q4 | $9.63K | Sell |
997
-1,063
| -52% | -$10.3K | ﹤0.01% | 6819 |
|
|
2024
Q3 | $38.3K | Sell |
2,060
-981
| -32% | -$18.2K | ﹤0.01% | 6287 |
|
|
2024
Q2 | $50.6K | Sell |
3,041
-12,338
| -80% | -$205K | ﹤0.01% | 6163 |
|
|
2024
Q1 | $267K | Sell |
15,379
-29,188
| -65% | -$507K | ﹤0.01% | 5610 |
|
|
2023
Q4 | $697K | Buy |
44,567
+20,494
| +85% | +$320K | ﹤0.01% | 5473 |
|
|
2023
Q3 | $1.19M | Buy |
24,073
+12,228
| +103% | +$605K | ﹤0.01% | 4695 |
|
|
2023
Q2 | $926K | Buy |
11,845
+3,722
| +46% | +$291K | ﹤0.01% | 4877 |
|
|
2023
Q1 | $736K | Sell |
8,123
-1,687
| -17% | -$153K | ﹤0.01% | 5041 |
|
|
2022
Q4 | $1.16M | Sell |
9,810
-7,692
| -44% | -$908K | ﹤0.01% | 4788 |
|
|
2022
Q3 | $3.18M | Buy |
17,502
+11,362
| +185% | +$2.06M | ﹤0.01% | 4060 |
|
|
2022
Q2 | $551K | Buy |
6,140
+2,137
| +53% | +$192K | ﹤0.01% | 5366 |
|
|
2022
Q1 | $622K | Buy |
4,003
+1,884
| +89% | +$293K | ﹤0.01% | 5279 |
|
|
2021
Q4 | $632K | Sell |
2,119
-239
| -10% | -$71.3K | ﹤0.01% | 5404 |
|
|
2021
Q3 | $1.36M | Buy |
2,358
+343
| +17% | +$198K | ﹤0.01% | 4852 |
|
|
2021
Q2 | $914K | Sell |
2,015
-1,160
| -37% | -$526K | ﹤0.01% | 5133 |
|
|
2021
Q1 | $1.71M | Buy |
3,175
+1,250
| +65% | +$673K | ﹤0.01% | 4377 |
|
|
2020
Q4 | $1.7M | Buy |
1,925
+1,735
| +913% | +$1.53M | ﹤0.01% | 4285 |
|
|
2020
Q3 | $120K | Buy |
+190
| New | +$120K | ﹤0.01% | 5346 |
|